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Objective: The Italian Society for Pediatric Infectious Diseases created a registry to determine
the management of pediatric acute mastoiditis (AM) in Italy. Methods: A cross-sectional
survey of paediatricians was conducted to evaluate hospitalization due to AM in Italian
pediatric wards between 1 January 2002, and 31 December 2013. Results: A total of
913 children (561 males, 61.4%) were included in this study. The annual number of AM
cases significantly increased during the study period (30 in 2002 and 98 in 2013) but only
among older children (‡4 years old; p = 0.02). AM complications occurred in 69 (7.6%) of
the children and sequelae were observed in 13 (1.4%) patients. Conclusion: The annual
number of pediatric AM cases admitted to Italian pediatric wards increased in the past few
years; this increase was strictly age-related. The risk of severe AM complications appeared
relatively low, and most AM cases could be treated conservatively.
KEYWORDS: acute mastoiditis • acute otitis media • antibiotic treatment • ear • pediatric otolaryngology
• pneumococcal vaccination
In the pre-antibiotic era, acute mastoiditis (AM)
was a common complication of acute otitis
media (AOM). Between 20% and 50% of
AOM cases progressed to AM, which has a
100% mortality rate [1,2]. The introduction of
antibiotics led to a sharp decline in AM inci-
dence. By the end of the last century, less than
1% of children with AOM suffered from AM
worldwide despite poor diagnostic and therapeu-
tic approaches in developing countries [3–6].
However, in recent years, despite the global inci-
dence of AM remaining stable [7] or continuing
to decline [8] in some countries, in others a sig-
nificant increase in the number of children suf-
fering from this disease was evidenced [9]. The
most common explanations include the emer-
gence of antibiotic resistance among AOM-
causing pathogens and restricted antibiotic use
in AOM treatment to prevent antibiotic misuse
in most of the recommendations for diagnosis
and therapy of this disease prepared
worldwide [10–13]. In addition, the inclusion of
the heptavalent and 13-valent pneumococcal
conjugate vaccines (PCV7 and PCV13, respec-
tively) in pediatric immunization schedules are
thought to contribute to this rise in AM cases
due to the serotype replacement phenomenon
[14–16]. In Italy, national AOM treatment guide-
lines were prepared in 2010 [17]. PCV7 was
included free of charge in the national immuni-
zation schedule in 2002 but vaccination coverage
was very low in many regions until 2007 and
PCV13, licensed in 2010, has only recently
reached >80% coverage in many of the most
populated regions [18]. The Italian Society for
Pediatric Infectious Diseases (SITIP) created a
pediatric AM registry to determine the preva-
lence of pediatric AM in Italy and to describe
the clinical findings, microbiology, treatment,
and complications of AM. In this study, we ana-
lyzed and described all AM cases between
2002 and 2013 that were reported by pediatri-
cians in the SITIP AM registry.
Material & methods
Study design & population
We conducted a cross-sectional survey of pedia-
tricians who participated in the SITIP AM
registry between 1 September 2013 and
31 December 2013. The SITIP AM registry
includes all pediatric infectious disease (PID)
specialists working in hospitals in Italy. Pediatri-
cians were e-mailed between 1 January 2014 and
31 January 2014 and asked to respond to a brief
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survey. Pediatricians were asked about AM patients <18 years
who had been admitted to their hospital between 1 January
2002 and 31 December 2013. Surveys could be returned by mail
or completed online using the web link provided in the e-mail.
Reminder e-mails were sent 1 month later, and reminder letters
and replacement surveys were sent to non-respondents after an
additional 8 weeks. This study was approved by the Ethics Com-
mittee of the University of Milan, Italy, and informed consent
was obtained from all participants.
Survey
The survey was prepared by two senior PID specialists (P.M.
and S.E.). A convenience sample of PID specialists were
administered the survey as a pilot. The survey was comprised
of four sections: (i) general characteristics of the AM patients;
(ii) clinical manifestations of the AM patients considered sug-
gestive of AM; (iii) radiological and laboratory tests used to
support AM diagnosis; and (iv) treatment prescribed for AM
(including the molecule, route of administration, dosage, and
duration of therapy) and its clinical outcome. All the data had
to be obtained from ambulatory or hospital medical records.
Among the general characteristics data regarding vaccine
administration were included. Particular attention was paid to
the influenza and pneumococcal vaccine administration.
Enrolled subjects were considered fully vaccinated against pneu-
mococcal infections when they have received, according to the
Italian vaccination schedule [18], two doses of PCV7 or
PCV13 at 3 and 5 months of age and a booster dose at about
1 year or two doses in the second year or a single dose between
2 and 5 years of age.
Statistical analysis
Continuous variables are presented as mean values ± standard
deviation or median with the interquartile range. Continuous
variables were analyzed using a two-sided Student’s test if they
were normally distributed (based on Shapiro–Wilk’s test) or a
two-sided Wilcoxon rank-sum test if they were not normally
distributed. Categorical variables are presented as numbers and
percentages and were analyzed using contingency tables and the
Chi-squared or Fisher’s exact test, as appropriate. AM patients
were stratified according to age (<2 years, between 2 and
4 years, and ‡4 years). Cochran-Armitage trend tests were used
to analyze patient enrolment during the study period. All statis-
tical analyses were two-tailed, and a p-value £0.05 was consid-
ered statistically significant.
Results
Twenty-five hospitals with PID wards participated in this
study. TABLE 1 summarizes the demographic characteristics of AM
cases included in the study. More than 80% of the cases were
diagnosed in five geographical regions (Lombardy, Lazio, Emilia,
Piedmont, Veneto); these regions had the highest number of par-
ticipating PID wards (14/25, 56.0%). Data on 913 AM patients
(561 males, 61.7%) with a mean admission age of 5.1 ± 3.8 years
(median, 4.0 years; range: 0.1–17 years) were included. Among
these patients, 246 (26.9%) were <2 years old, 204 (22.3%) were
between 2 and 4 years old, and 463 (50.7%) were ‡4 years old.
No differences in ethnicity and baseline clinical information were
observed between these age groups.
FIGURE 1 shows the distribution of hospitalized AM cases
according to age. The annual number of AM diagnoses signifi-
cantly increased during the study period (p = 0.03). This
increase was statistically significant for older (‡4 years old,
p = 0.02) but not younger (<2 years old, p = 0.69; 2–4 years
old, p = 0.22) patients.
The number of AM diagnoses sharply increased after 2010.
We had data on PCV7 and PCV13 vaccination for 362 children;
202 (55.8%) of these children were not fully vaccinated. Only
18 of 108 (16.7%) children with AM were vaccinated with either
PCV7 or PCV13 before 2010. After 2010, 142 of 254 (55.9%;
p < 0.0001) children with AM were fully vaccinated.
TABLE 2 summarizes the clinical symptoms and manifestations of
the children with AM. Before hospitalization, only 667 (72.3%)
of the children had at least one symptom typical of AOM or a
documented AOM diagnosis via otoscopy. This was significantly
more common among children <2 years than in older patients
(p < 0.001). Fever, othalgia, irritability, anorexia, and rhinitis
were significantly more common among children <2 years than
in the other age groups. Rhinorrea, retroauricolar erythema, and
retroauricolar edema were also significantly more common
among children <2 years than in the other age groups.
AM microbiology was evaluated in 177 subjects. Exudate
was obtained from the ear canal for culturing primarily via
tympanocentesis in 147 (83.0%) patients or puncturing of
retro-auricular abscesses while under local anesthesia in
5 (2.8%) patients; in 25 (14.1%) patients, exudate was col-
lected pre-operatively. In 78 (44.1%) of the cases, no pathogen
was isolated. The most frequently isolated pathogen was Pseu-
domonas aeruginosa (29.4%), followed by Staphylococcus aureus
(6.2%); in these cases, exudate was collected from the ear canal.
Streptococcus pneumoniae was identified in 10 (5.7%) cases; in
these cases, exudate was obtained pre-operatively.
TABLE 3 summarizes the radiographic examinations performed at
diagnosis. AM was diagnosed or confirmed using radiographic
examinations in 477 (51.7%) cases. In 415 (87.0%) cases, imaging
was used to confirm the clinical suspicion of AM. However, in
62 (13.0%) cases, AM was diagnosed using CT scans, which were
performed for neurological problems with no clinical evidence of
AM. Typically, these diagnoses were made after observing mastoid
changes consistent with AM and occurred primarily among older
patients and in more recent years. CT scans of the mastoid were
most common (272/913 children, 29.8%), followed by that of the
brain (107/913 children, 11.7%). Brain MRI had a limited role in
this cohort (67/913 children, 7.3%), and cranic x-rays were used
in less than 5% of the cases (32/913 children, 3.5%).
During hospitalization, most patients (840/913, 92.0%)
underwent intravenous antibiotic treatment. However, in
288 (34.3%) cases, patients were switched to oral antibiotics
after 3–7 days. More than 80% of patients received monother-
apy consisting of a third-generation cephalosporin (primarily
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ceftriaxone) at a proper dosage. The median duration of antibi-
otic therapy was 13 days (ranging from 7 to 28 days). After a
positive AM diagnosis, 79 (8.5%) patients underwent surgery.
Mastoidectomy was performed in 40 (50.6%) cases, the retro-
auricolar abscess was drained in 12 (15.2%), and explorative
miringotomy was performed in 27 (34.1%).
TABLE 4 summarizes the evolution of AM after diagnosis. The
median duration of hospitalization was 7.1 days (range: 0–
43 days). Complications occurred in 69 (7.6%) cases, but there
were no differences between age groups. Thrombosis of the
ipsilateral sinus was the main complication observed (22/913,
2.4%), followed by facial palsy (16/913, 1.8%). In
900 (98.6%) cases, patients were considered cured after dis-
charge: sequelae were observed in 13 (1.4%) patients. However,
no patients died.
Discussion
This 12-year retrospective study of pediatric AM provides
updated information on the frequency with which AM is diag-
nosed among Italian children and on how supposed or demon-
strated AM is treated by PID specialists in Italian hospitals.
Between 2002 and 2013, the annual number of pediatric
AM cases admitted to the Italian hospitals in different regions
of Italy progressively increased. The increase was strictly
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Figure 1. Age distribution of acute mastoiditis cases in the
participating hospitals during 2002–2013.
Table 1. Characteristics of the children with a diagnosis of acute mastoiditis who were included in the
study.
n (%) <2 years
n (%)
2–4 years
n (%)
‡4 years
n (%)
Total patients 913 246 204 463
Geographic regions†
Lombardy 217 (23.5) 68 (27.6) 37 (18.1) 112 (24.2)
Lazio 176 (19.1) 34 (13.8) 49 (24.0) 92 (19.9)
Emilia 148 (16.0) 45 (18.3) 38 (18.6) 63 (13.6)
Piedmont 118 (12.8) 36 (14.6) 30 (14.8) 52 (11.2)
Veneto 115 (12.5) 32 (13.1) 17 (8.3) 59 (12.7)
Other Italian regions 149 (16.1) 31 (12.6) 33 (16.2) 85 (18.4)
Gender
Male 561 (61.4) 153 (62.2) 123 (60.3) 285 (61.6)
Female 352 (38.6) 93 (37.8) 81 (39.7) 178 (38.4)
Age (years)
Mean ± SD 5.1 ± 3.8 1.1 ± 0.4 3.0 ± 0.5 8.0 ± 3.0
Median (IQR) 4.0 (5.6) 1.2 (0.6) 3.1 (0.9) 7.4 (4.9)
Ethnicity
Caucasian 856 (93.8) 230 (93.5) 190 (93.1) 436 (94.2)
Other clinical information
Born at term 703 (76.9) 196 (79.7) 155 (75.9) 352 (76.0)
Breastfeeding for at least 1 month 570 (62.4) 163 (66.2) 125 (61.3) 282 (60.9)
History of allergy 52 (5.7) 10 (4.1) 11 (5.4) 31 (6.7)
†The sum does not add up to the total due to a few missing values.
IQR: Interquartile range; SD: Standard deviation. No significant differences were observed.
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age-related and significantly higher among children aged
‡4 years. We were unable to calculate the actual incidence and
prevalence of AM in children in these geographic areas since
not all AM cases in each region were evaluated. However, the
increasing number of AM cases is consistent with reports pub-
lished in the past 15 years [7]. Thus, the increase in pediatric
AM may be due to several factors such as the increase in
AOM-causing bacteria that have antibiotic resistance, serotype
replacement following the administration of PCV, changes to
health service access, and above all, the practice of ‘watchful
waiting’ for AOM [19]. In this study, watchful waiting seems to
have played a predominant role in the increase in AM inci-
dence. The increase in AM diagnoses was particularly evident
after 2010. In 2010, national guidelines for Italy were pub-
lished that recommended watchful waiting for select AOM
cases and restricted antibiotic use in older children [17].
The number of AM diagnoses increased despite the imple-
mentation of regional programs that improved the administra-
tion of PCV to infants and children. AM cases among
children who were fully vaccinated with PCV7 or PCV13
increased over time, which could suggest that these vaccines
offer poor protection against AM. Several studies have
reported conflicting results on the impact of PCV7 or
PCV13 on AM incidence. One study has reported a decrease
in AM incidence after the introduction of PCV7 [16]; however,
another study reported no change or even an increase in AM
incidence [20]. Recently, one study observed a sudden initial
decline in AM incidence in Colorado [15]. In that study, AM
incidence eventually returned to pre-PCV7 levels, which may
be explained by replacement phenomenon [15]. PCV13 has
also appeared to reduce AM incidence [21]; however, not
enough time has passed to determine whether possible sero-
type replacement may lead to an increase in incidence [21]. In
our study, the low incidence of AM pneumococcal cases may
explain why we did not observe an impact by either PCV7 or
PCV13 vaccination. In addition, the number of patients for
whom microbiological studies were performed was too small
to draw firm conclusions about the effect of these vaccines on
AM incidence.
However, it is possible that the increase in the annual num-
ber of AM cases diagnosed in the participating hospitals does
not reflect the real pediatric AM incidence in Italy. This study
was a non-population-based study. A recent evaluation has
shown that non-population-based studies frequently lead to
reports of increased AM incidence, while population-based
studies do not [5]. Thus, the changes in AM incidence found in
the literature could be attributed to changes in how studies are
conducted rather than actual changes in disease incidence. In
addition, the merging of health care facilities may also lead to
the perception that AM incidence has increased [22].
Table 2. Acute mastoiditis symptoms diagnosis according to patient age.
n (%) <2 years
n (%)
2–4 years
n (%)
‡4 years
n (%)
p-value
Total patients 913 246 204 463
Symptoms
Fever ‡38˚C 599 (65.3) 195 (79.3) 137 (67.2) 264 (57.0) <0.001
Othalgy 665 (72.8) 142 (57.7) 148 (72.6) 375 (81.0) <0.001
Irritability 139 (15.2) 52 (21.1) 38 (18.6) 49 (10.6) <0.001
Anorexia 43 (4.7) 17 (6.9) 13 (6.4) 13 (2.8) 0.02
Vomit 45 (4.9) 11 (4.5) 5 (2.5) 29 (6.3) 0.10
Sleeping disturbance 74 (8.1) 21 (8.5) 16 (7.8) 37 (8.0) 0.96
Rhinitis 133 (14.6) 58 (23.6) 36 (17.7) 39 (8.4) <0.001
Cough 62 (6.8) 23 (9.4) 16 (7.8) 23 (5.0) 0.07
Signs
Rhinorrea 130 (14.2) 55 (22.3) 25 (12.3) 50 (10.8) 0.007
AOM 167 (18.3) 54 (21.9) 37 (18.1) 76 (16.4) 0.37
Othorrea 175 (19.2) 40 (16.3) 36 (17.6) 99 (21.4) 0.79
Otitis media with effusion 234 (25.6) 66 (26.8) 49 (24.0) 119 (25.7) 0.56
Retroauricolar erythema 619 (67.8) 190 (77.2) 133 (65.2) 296 (63.9) 0.006
Retroauricolar edema 637 (69.8) 199 (80.9) 139 (68.1) 299 (64.6) <0.001
Retroauricolar pain 592 (64.8) 152 (61.8) 130 (63.7) 310 (66.9) 0.74
AOM: Acute otitis media.
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The criteria for diagnosing AM remain controversial and
change over time, which could possibly result in false results
and in overestimation of the incidence of AM. In this study,
we found more than 25% of the children with AM diagnoses,
a prevalence only slightly lower than that observed in a study
of Swedish children who did not have symptoms of a previous
AOM episode and, consequently, should have not been
included among AM cases [23]. CT or MR imaging has been
shown to contribute to AM diagnoses; however, these tests can
lead to false acute AM diagnosis. When CT and MR scans are
performed for clinical problems besides AM, mastoid images
consistent with AM can be observed despite the lack of any
Table 3. Radiographic examinations performed at diagnosis according to patient age.
n (%) <2 years
n (%)
2–4 years
n (%)
‡4 years
n (%)
p-value
Total patients 913 246 204 463
Cranic x-ray
No 881 (96.5) 235 (95.5) 199 (97.5) 447 (96.5) 0.55
Yes 32 (3.5) 11 (4.5) 5 (2.5) 16 (3.5)
Brain computed tomography
No 806 (88.3) 231 (93.9) 177 (86.8) 398 (86.0) 0.001
Yes 107 (11.7) 15 (6.1) 27 (13.2) 65 (14.0)
Mastoid computed tomography
No 641 (70.2) 171 (69.5) 148 (72.5) 322 (69.5) 0.94
Yes 272 (29.8) 75 (30.5) 56 (27.5) 141 (30.5)
Brain magnetic resonance
No 846 (92.7) 234 (95.1) 187 (91.7) 425 (91.8) 0.19
Yes 67 (7.3) 12 (4.9) 17 (8.3) 38 (8.2)
Table 4. Evolution of acute mastoiditis after diagnosis according to patient age.
n (%) <2 years
n (%)
2–4 years
n (%)
‡4 years
n (%)
p-value
Total patients 913 246 204 463
Duration of hospitalization
Mean ± standard deviation, days 7.1 ± 5.1 7.2 ± 5.1 7.7 ± 5.7 6.7 ± 4.9 0.69
Patients with complications 69 (7.6) 13 (5.3) 19 (9.3) 37 (8.0) 0.14
Thrombosis of the ipsilateral sinus 22 (2.4) 5 (2.0) 5 (2.4) 12 (2.6) 0.76
Facial palsy 16 (1.8) 3 (2.8) 4 (1.9) 9 (1.9) 0.70
Subperiosteal abscess 12 (1.3) 2 (0.8) 3 (1.5) 7 (1.5) 0.43
Dizziness 10 (1.1) 2 (0.8) 2 (0.9) 6 (1.3) 1.00
Intracranial abscess 5 (0.5) 0 (0.0) 3 (1.5) 2 (0.4) 0.09
Meningitis 3 (0.3) 0 (0.0) 2 (0.9) 1 (0.2) 1.00
Fistulation 1 (0.1) 1 (0.4) 0 (0.0) 0 (0.0) 0.45
Patients with sequelae 13 (1.4) 3 (2.8) 4 (1.9) 6 (1.3) 0.70
Hearing loss 7 (0.8) 2 (0.8) 3 (1.5) 2 (0.4) 0.66
Facial palsy 4 (0.4) 1 (0.4) 1 (0.5) 2 (0.4) 1.00
Neurologic delay 2 (0.2) 0 (0.0) 0 (0.0) 2 (0.4) 0.54
Patients who died 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) –
AM in children Original Research
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clinical signs and symptoms [3,14]. Thus, if these cases are
included in epidemiological evaluations of AM, AM incidence
will be overestimated. This seems confirmed in this study
where 13.0% of AM patients who had a radiological examina-
tion underwent a brain CT scan for neurological problems,
which revealed a mastoid modification that led to AM diagno-
sis despite no previous clinical suspicion of this disease. Inter-
estingly, the use of MR imaging in our study compared to CT
scans was limited. However, MR imaging should be recom-
mended instead of CT scans in children since it does not use
radiation but still improves the efficiency of AM diagnosis [24].
We note that the microbiological evaluations conducted in
this study primarily identified P. aeruginosa and S. aureus,
which were mostly isolated from the tympanocentisis in the ear
canal. This is surprising because both these pathogens are not
frequently found in samples taken during surgery or via aspira-
tion from retroauricular abscess which have the greatest proba-
bility to identify the true cause of AM [14]. P. aeruginosa is the
most common pathogen for chronic suppurative OM and,
together with S. aureus, the most common cause of external
otitis. In contrast, in the population enrolled in this study,
S. pneumoniae, usually considered the most common etiologic
agent of AM [14], was identified in a small number of children,
just when appropriate samples for culture were taken. This sug-
gests that both the first pathogens represent contamination
from or simultaneous infection of the ear canal. Despite similar
findings and conclusions that have been previously
reported [25,26], they suggest that in a not marginal number of
cases AM cases included in this survey were not true AM.
However, these misleading results did not influence the antibi-
otic therapy chosen. Most of the children received an intrave-
nous treatment of ceftriaxone. Ceftriaxone is a third-generation
cephalosporin that is active against most AOM-causing patho-
gens, including S. pneumoniae but has poor efficacy against
P. aeruginosa and S. aureus. This suggests that pediatricians did
not consider the microbiological findings and treated children
according to the national guidelines mainly devoted to the
eradication of S. pneumoniae and to cover potential intracranial
spread of the infection [17].
Our findings on the evolution of AM, the need for surgery,
and the incidence of AM complications were similar to those
of other studies [23,25,26]. Together, these data seem to indicate
that the risk of severe AM complications appears relatively low.
Most AM cases can be treated conservatively according to the
national guidelines for complicated AOM. However, compari-
sons between these studies remain difficult due to the different
criteria used for AM diagnosis even if it is reasonable to think
that the incidence of severe AM complications may be higher
than that reported in the studies in which stringent criteria for
AM diagnosis are followed.
In conclusion, this study highlights how difficult it is to
quantify AM incidence in children when no population-
based studies are performed. Moreover, the lack of consis-
tent diagnostic criteria and therapeutic approaches for AM
in the pediatric population makes comparing data from dif-
ferent studies nearly impossible. International guidelines for
managing AM are needed to standardize approaches to AM
and to identify risk factors for AM complications. On the
contrary, several problems in the evaluation of data regard-
ing incidence of AM as well as the role of vaccine preven-
tion and AOM therapy in conditioning AM occurrence will
continuously arise.
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Key issues
• A slight but significant increase in acute mastoiditis (AM) incidence has been reported in several countries in the past few years.
• In Italy, the annual number of pediatric AM cases progressively increased between 2002 and 2013 in an age-dependent manner.
• The number of AM cases increased despite the implementation of regional programs to improve the administration of pneumococcal
conjugate vaccines to infants and children.
• AM symptoms were observed more often among children <2 years old than among older children.
• AM diagnoses were made or confirmed by radiographic examinations in half of the cases.
• The risk of severe AM complications appeared relatively low, and most AM cases could be treated conservatively.
• International guidelines for managing AM are needed to standardize approaches to AM and to identify risk factors for
AM complications.
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